Search

Your search keyword '"Carlo, Antozzi"' showing total 209 results

Search Constraints

Start Over You searched for: Author "Carlo, Antozzi" Remove constraint Author: "Carlo, Antozzi"
209 results on '"Carlo, Antozzi"'

Search Results

1. Targeting autoimmune mechanisms by precision medicine in Myasthenia Gravis

2. The impact of PM2.5, PM10 and NO2 on Covid-19 severity in a sample of patients with multiple sclerosis: A case-control study

3. Neutralizing antibodies to Omicron after the fourth SARS-CoV-2 mRNA vaccine dose in immunocompromised patients highlight the need of additional boosters

4. Muscle and Muscle-like Autoantigen Expression in Myasthenia Gravis Thymus: Possible Molecular Hint for Autosensitization

5. Complement Activation Profile in Myasthenia Gravis Patients: Perspectives for Tailoring Anti-Complement Therapy

6. Safety and efficacy of zilucoplan in patients with generalised myasthenia gravis (RAISE): a randomised, double-blind, placebo-controlled, phase 3 study

7. From Traditional to Targeted Immunotherapy in Myasthenia Gravis: Prospects for Research

8. miR-146a in Myasthenia Gravis Thymus Bridges Innate Immunity With Autoimmunity and Is Linked to Therapeutic Effects of Corticosteroids

9. Whole miRNome profiling in myasthenia gravis thymus: novel insights into the molecular events underlying autoimmunity

10. Whole miRNome sequencing in myasthenia gravis thymus reveals dysregulated miRNA/target gene networks implicated in autoimmunity

11. The effect of air pollution on COVID‐19 severity in a sample of patients with multiple sclerosis

12. Amifampridine phosphate in the treatment of muscle-specific kinase myasthenia gravis: a phase IIb, randomized, double-blind, placebo-controlled, double crossover study

13. The impact of PM2.5, PM10 and NO2 on Covid-19 severity in a sample of patients with multiple sclerosis: A case-control study

14. Survival gain in glioblastoma patients treated with dendritic cell immunotherapy is associated with increased NK but not CD8+ T cell activation in the presence of adjuvant temozolomide

15. When myasthenia gravis is deemed refractory: clinical signposts and treatment strategies

17. MicroRNA quali biomarcatori di risposta alle terapie immunosoppressive nella miastenia gravis: prospettive per una medicina personalizzata

18. Post-intervention Status in Patients With Refractory Myasthenia Gravis Treated With Eculizumab During REGAIN and Its Open-Label Extension

19. SERUM AUTOANTIBODY LOWERING BY THE ANTI-FCRN MONOCLONAL ANTIBODY, NIPOCALIMAB, CORRELATES WITH CLINICAL IMPROVEMENT IN GENERALIZED MYASTHENIA GRAVIS PATIENTS

20. SARS-CoV-2 serology after COVID-19 in multiple sclerosis: An international cohort study

21. COVID-19 Severity in Multiple Sclerosis: Putting Data Into Context

22. Disease-Modifying Therapies and Coronavirus Disease 2019 Severity in Multiple Sclerosis

23. Anti-Spike IgG in multiple sclerosis patients after BNT162b2 vaccine: An exploratory case-control study in Italy

24. Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial

25. L'aferesi terapeutica nella miastenia grave

26. Role Preferences of People with Multiple Sclerosis: Image-Revised, Computerized Self-Administered Version of the Control Preference Scale.

27. Expansion of effector and memory T cells is associated with increased survival in recurrent glioblastomas treated with dendritic cell immunotherapy

28. An optimized method for manufacturing a clinical scale dendritic cell-based vaccine for the treatment of glioblastoma.

29. Long-term efficacy and safety of eculizumab in Japanese patients with generalized myasthenia gravis: A subgroup analysis of the REGAIN open-label extension study

30. Atypical Post-Injection Reactions with Delayed Onset Following Glatiramer Acetate 40 mg: Need for Titration?

31. Toll-like receptors 7 and 9 in myasthenia gravis thymus: amplifiers of autoimmunity?

32. Inflammation and Epstein-Barr Virus Infection Are Common Features of Myasthenia Gravis Thymus: Possible Roles in Pathogenesis

33. Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study

34. Development and validation of the myasthenia gravis telescore (MGTS)

35. Multimorbidity in multiple sclerosis: Impact on disability, quality of life and health status

36. Epstein-Barr virus in tumor-infiltrating B cells of myasthenia gravis thymoma: an innocent bystander or an autoimmunity mediator?

37. Validity, reliability, and sensitivity to change of the myasthenia gravis activities of daily living profile in a sample of Italian myasthenic patients

38. A propensity score analysis for comparison of T-3b and VATET in myasthenia gravis

39. Validation of the italian version of the 15‐item Myasthenia Gravis Quality‐of‐Life questionnaire

40. miR-146a in Myasthenia Gravis Thymus Bridges Innate Immunity With Autoimmunity and Is Linked to Therapeutic Effects of Corticosteroids

41. Severe multiple sclerosis reactivation during prolonged lymphopenia after dimethyl fumarate discontinuation

42. Early effect of dalfampridine in patients with MS: A multi-instrumental approach to better investigate responsiveness

43. Increased expression of Toll-like receptors 7 and 9 in myasthenia gravis thymus characterized by active Epstein–Barr virus infection

44. Italian recommendations for the diagnosis and treatment of myasthenia gravis

45. Survival gain in glioblastoma patients treated with dendritic cell immunotherapy is associated with increased NK but not CD8+ T cell activation in the presence of adjuvant temozolomide

46. Interpreting Genetic Variants in Titin in Patients With Muscle Disorders

47. Validation of the besta neurological institute rating scale for myasthenia gravis

48. MuSK autoantibodies in myasthenia gravis detected by cell based assay - A multinational study

49. When myasthenia gravis is deemed refractory: clinical signposts and treatment strategies

50. Survival gain in glioblastoma patients treated with dendritic cell immunotherapy is associated with increased NK but not CD8

Catalog

Books, media, physical & digital resources